OncoMatch/Clinical Trials/NCT02897700
A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast
Is NCT02897700 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate and cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM) for breast cancer.
Treatment: Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate · cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM) — The overarching purpose of this study is to determine if the mainstay chemotherapeutic regimens represented by several genotoxic agents including but not limited to Cyclophosphamide, Doxorubicin, Epirubicin, Fluorouracil and Methotrexate (CDEFM), in the format of either a single agent or combinations are safe, tolerable, and effective in the treatment of patients with infiltrating ductal carcinoma of breast.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Required: Stage IA
Excluded: Stage IV
Performance status
WHO 0–1
Prior therapy
Cannot have received: cancer chemotherapy
No prior or concurrent cancer-associated chemotherapy, no initiation of new hormonal therapy
Lab requirements
Blood counts
WBC ≥ 3,000/μl; ANC ≥ 1,500/μl; Platelet count ≥ 100,000/μl; HGB ≥ 10 g/dl and not transfusion dependent
Liver function
ALT and AST ≤ 10% above upper limit of normal
Patients must have adequate hematopoietic function as evidenced by: white blood cells (WBC) ≥ 3,000/μl absolute neutrophil count (ANC) ≥ 1,500/μl Platelet count ≥ 100,000/μl hemoglobin (HGB) ≥ 10 g/dl and not transfusion dependent; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 10% above upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify